Strata Critical Medical, Inc.
Strata Critical Medical, Inc. (SRTA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
srta · stock forecast · 6 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$7.25
Consensus
$7.25
+25.2% upside
Low
$7.25
Median: $7.25 · Last Close: $5.79
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $6.05 | ↑ 4.51% |
1-day model range: $6.01–$6.09. Peak: $6.09 (+4.51%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $5 | -15.2% |
| 2028 | $5 | -22.3% |
| 2029 | $4 | -25.9% |
| 2030 | $4 | -27.8% |
| 2031 | — | -28.8% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SRTA · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-17 | Lake Street | Maintains | Buy→Buy |
| 2024-10-29 | JP Morgan | Maintains | Overweight→Overweight |
| 2023-08-22 | Citigroup | Maintains | Buy→Buy |
| 2023-08-10 | Credit Suisse | Maintains | Outperform→Outperform |
| 2023-05-12 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-05-12 | Credit Suisse | Maintains | Outperform→Outperform |
| 2023-03-15 | Credit Suisse | Maintains | Outperform→Outperform |
| 2023-03-15 | JP Morgan | Maintains | Overweight→Overweight |
| 2023-03-15 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-01-26 | JP Morgan | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Strata Critical Medical, Inc. (SRTA) stock. Of the recent 19 rating actions, 0 were upgrades and 0 were downgrades. 6 analysts currently cover SRTA.
Analyst Recommendation Trends
SRTA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$245M
↓ 10.7% YoY
Revenue Next Year
$214M
↓ 12.6% YoY
EPS This Year
$-0.34
EPS Next Year
$-0.01
↓ 97.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast SRTA EPS of $-0.34 for the current fiscal year, based on estimates from 1 analysts. The SRTA revenue forecast is $245M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SRTA stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SRTA price target is $7.25 (+25.2% upside), with an analyst consensus of Buy.
The SRTA short-term stock prediction for tomorrow is $6.05 (+4.51%). The SRTA stock price prediction for 2027 estimates an average of $5. The SRTA stock prediction for 2030 projects a range of $4–$5.
Strata Critical Medical, Inc. trades on NASDAQ under the ticker SRTA. The SRTA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
SRTA forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month SRTA price target is $7.25, with a high forecast of $7.25 and a low of $7.25. The median price target is shown in the chart above when available. This implies +25.2% potential upside from the current price of $5.79.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.